PSFG
BIB icon

Park Square Financial Group’s ProShares Ultra NASDAQ Biotechnology BIB Stock Holding History

Park Square Financial Group’s Portfolio BIB Stock Details BIB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-316
Closed -$14.5K – 327
2025
Q2 		$14.5K Hold
316
– – 0.01% 530
2025
Q1 		$15.2K Hold
316
– – 0.01% 500
2024
Q4 		$16K Buy
+316
New +$18.7K 0.01% 483

Other funds holding BIB

Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
CIC
Chase Investment Counsel Charlottesville, Virginia $381M AUM 69.8% 1-Year Est. Return
CIA
Capital Investment Advisors Atlanta, Georgia $6.84B AUM 17.28% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
PWM
Palumbo Wealth Management Great Neck, New York $410M AUM 32.56% 1-Year Est. Return
TFA
Toth Financial Advisory Leesburg, Virginia $1.02B AUM 28.36% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
PNC Financial Services Group
PNC Financial Services Group Pittsburgh, Pennsylvania $173B AUM 20.72% 1-Year Est. Return

Park Square Financial Group's BIB Position: Q3 2025 in Review

Park Square Financial Group sold out of ProShares Ultra NASDAQ Biotechnology (BIB) in Q3 2025, closing a stake of 316 shares — an estimated $14.5K sold.

Park Square Financial Group first reported a position in BIB in Q4 2024 and held it in 3 quarters. The position peaked at $16K in Q4 2024. 19 funds tracked by Wall St. Rank hold BIB as of Q3 2025.

  • Park Square Financial Group reported no remaining ProShares Ultra NASDAQ Biotechnology position as of Q3 2025 after selling out during the quarter.
  • Park Square Financial Group sold 316 ProShares Ultra NASDAQ Biotechnology shares in Q3 2025, an estimated $14.5K.
  • Park Square Financial Group first reported a position in ProShares Ultra NASDAQ Biotechnology in Q4 2024 and held it in 3 quarters.
  • Park Square Financial Group's ProShares Ultra NASDAQ Biotechnology position peaked at $16K in Q4 2024.
  • 19 funds tracked by Wall St. Rank held ProShares Ultra NASDAQ Biotechnology as of Q3 2025.

Based on Park Square Financial Group's 13F filing for Q3 2025, filed 12 Nov 2025.